New spike map shows how SARS-CoV-2 variants dodge key antibodies
Antibodies are an important defense against SARS-CoV-2, but the virus continues to evolve ways to evade them. Now, researchers have mapped how antibodies target a key region of the virus's spike protein, how they neutralize the virus and how emerging variants escape them.
A recent study has mapped how antibodies interact with a key region of the SARS-CoV-2 spike protein, revealing how emerging variants can evade this immune defense. The research, led by scientists from the Chinese Academy of Sciences, focused on the N-terminal domain (NTD) of the spike protein. By analyzing antibody-antigen interactions using structural and mechanistic approaches, the team classified NTD-targeting antibodies into nine distinct groups, each targeting a unique spatial epitope.
Most antibodies require bivalent binding for effective neutralization, while specific antibodies from the NTD-5 and NTD-9 classes can destabilize the spike protein by shedding its S1 subunit, thereby inhibiting viral entry.
The study profiled 41 monoclonal antibodies across the original SARS-CoV-2 strain, the delta variant, and 17 omicron subvariants, creating an "epitope-resolved escape atlas." This atlas highlights how different NTD antibody classes respond to viral evolution, with some broad-reactive antibodies losing effectiveness as omicron subvariants emerged.
The researchers identified three primary immune evasion strategies: disrupting antibody-contact residues, glycan shielding, and conformational remodeling. A notable example is the KP.3.1.1 omicron subvariant, which features a serine deletion at position 31 (ΔS31) that introduces a new glycosylation site at N30 and reshapes the nearby S27–R34 region.
This combination of glycan shielding and conformational remodeling impairs recognition by antibodies from both the NTD-5 and NTD-9 classes. The findings provide a comprehensive framework connecting NTD epitope organization, antibody neutralization, and viral immune escape, potentially guiding the development of more resilient antibodies and vaccines against continued antigenic drift in SARS-CoV-2.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
